The major pharmaceutical company Eli Lilly has just demonstrated efficacy of their Alzheimer’s drug donanemab in phase 2 clinical human trials. The results are a major development for the treatment of a disease that currently affects six million Americans, but that has almost no methods of alleviation. Alzheimer’s is caused by the buildup of tau […]
The post New Alzheimer’s Treatment Shows Real Promise in Slowing Cognition Decline Using Antibody in Human Trials appeared first on Good News Network.
The major pharmaceutical company Eli Lilly has just demonstrated efficacy of their Alzheimer’s drug donanemab in phase 2 clinical human trials. The results are a major development for the treatment of a disease that currently affects six million Americans, but that has almost no methods of alleviation. Alzheimer’s is caused by the buildup of tau
The post New Alzheimer’s Treatment Shows Real Promise in Slowing Cognition Decline Using Antibody in Human Trials appeared first on Good News Network.